Business
ZYUS Life Sciences Announces Amendment to Subleases and Promissory Note Agreement
ZYUS Life Sciences Corporation (the "Company") (TSXV: ZYUS), a clinical‑stage life sciences company focused on the development and commercialization of novel non‑opioid drug candidates for pain management, is pleased to announce it has entered into an amendment to its subleases with its landlord pursuant to which, among other things, the Company has extended the term of its existing subleases to January 31, 2030. The Company also entered into a promissory note agreement dated January 29, 2026, p
About this update from Zyus Life Sciences Corporation
[{"type":"text","content":"/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/","length":90,"tagName":"p","attribs":{}},{"type":"text","content":"SASKATOON, SK, Feb. 4, 2026 /CNW/ - ZYUS Life Sciences Corporation (the "Company") (TSXV: ZYUS), a clinical‑stage life sciences company focused on the development and commercialization of novel non‑opioid drug candidates for pain management, is pleased to announce it has entered into an amendment to its subleases with its landlord pursuant to which, among other things, the Company has extended the term of its existing subleases to January 31, 2030. The Company also entered into a promissory note agreement dated January 29, 2026, pursuant to which certain trade payables owing to its landlord were converted into an interest-bearing promissory note (the "Promissory Note"). The Promissory Note has a principal amount of C$4,409,085.43 and bears an interest rate of 8% per annum. Interest is payable quarterly, with interest-only payments commencing on May 11, 2026. Principal and interest payments will commence on May 1, 2027, and the Promissory Note will mature and be repaid in full as of February 1, 2030.","length":1034,"tagName":"p"},{"type":"image","alt":"ZYUS Life Sciences Logo (CNW Group/ZYUS Life Sciences Corporation)","displaySize":"","headline":null,"caption":"ZYUS Life Sciences Logo (CNW Group/ZYUS Life Sciences Corporation)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":162,"url":"https://media.zenfs.com/en/cnwgroup.com/92a7213cb14aca933d41923253285ad1"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/yqe8BVvMzFIkwgzRzRoDrQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTI4NjtjZj13ZWJw/https://media.zenfs.com/en/cnwgroup.com/92a7213cb14aca933d41923253285ad1","width":400,"height":162}},"href":"https://mma.prnewswire.com/media/2877650/ZYUS_Life_Sciences_Corporation_ZYUS_Life_Sciences_Announces_Amen.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The Company will be amending the offering document dated January 12, 2026 with respect to the offering (the "LIFE Offering") pursuant to and in accordance with the "listed issuer financing exemption" from the prospectus requirement available under section 5A.2 of National Instrument 45-106 – Prospectus Exemptions, as amended by Coordinated B...